Rallybio Corp.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare

The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir

Najat Khan has built her career at the intersection of drug development and technological innovation. As chief R&D and commercial officer at Recursion, she is helping to scale one of biotech’s (or

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b